Will Castle Biosciences stock go up?

According to Danelfin AI, Castle Biosciences has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.78%) is +2.96% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Castle Biosciences stock?

The Castle Biosciences target price is $24.13 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Castle Biosciences stock right now?

Castle Biosciences has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (53.78%) is +2.96% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Castle Biosciences stock is a good buy .

Is Castle Biosciences undervalued right now?

Based on analysts, the average price target downside for Castle Biosciences is 0.00% (1Y). According to Danelfin AI, Castle Biosciences has today an AI Score of 5/10 (Hold Rating).

What was the price range of Castle Biosciences stock over the past 12 months?

The Castle Biosciences stock price range over the past 12 months has been $14.65 - $43.04.

What is going on with Castle Biosciences stock in the last 3 months?

The Castle Biosciences stock performance in the last quarter has been -3.67%.

Does Castle Biosciences offer dividend payments?

No, Castle Biosciences does not currently pay dividends.

What is the current market capitalization of Castle Biosciences?

Castle Biosciences's market cap is $731.25M, as of 2026-07-03 08:00.

Castle Biosciences Inc (CSTL) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

CSTL AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+2.24%
Direction and strength of recent price movements
Valuation+1.27%
How the stock is priced relative to its fundamentals
Earnings Quality+0.40%
Stability and reliability of reported earnings
Size & Liquidity+0.12%
Company size and trading liquidity

Sentiment-0.88%
How analysts and the market view the stock
Profitability-0.19%
Profitability and operating efficiency metrics

CSTL probability advantage of beating the market (3M):

+2.96%

AI Score

Hold

Castle Biosciences (CSTL) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +2.96% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of CSTL (53.78%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
CSTL probability advantage of beating the market (3M)+2.96%
CSTL probability of beating the market (3M)53.78%

CSTL probability advantage of beating the market (3M): +2.96%

The AI-powered overall analysis of Castle Biosciences (CSTL) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of CSTL:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+0.94%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.83%
Technical	Chart Pattern (252d)	figure_79	N/A	+0.73%
Sentiment	Sentiment Impact (Long Tail)	-	N/A	-0.45%
Sentiment	Industry (GICS)	Health Care Providers & Services	N/A	-0.44%
Fundamental	Operating Cash Flow (Qtr Discrete)	-22.13		+0.40%
Technical	Alpha Last Day	-0.02%		+0.39%
Technical	Chart Pattern (504d)	figure_95	N/A	+0.33%
Technical	Performance (YTD)	-0.38%		+0.32%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.31%
Sentiment	Upgrade to unlock			+0.28%
Technical	Upgrade to unlock			-0.28%
Technical	Upgrade to unlock			-0.26%
Technical	Upgrade to unlock			+0.23%
Fundamental	Upgrade to unlock			+0.23%

Rest of Alpha Signals: +0.02%

CSTL probability advantage of beating the market (3M)Total:+2.96%
CSTL AI Score

Significant changes Vs previous day

CSTL Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$24.13
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

CSTL Proven Hold Signal & Price Forecast

This is the price chart for CSTL from January 2, 2026 until today. The chart indicates, in yellow, the 95 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

CSTL Average Past Performance & Win Rate

Three months after its 1061 Hold signals since July 2026, CSTL had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1061 Past CSTL Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+23.29%
Average Alpha				+8.31%
Win Rate (% Positive Perf.)				52.64%
% Positive Alpha				44.23%

CSTL Frequently Asked Questions

Will Castle Biosciences stock go up?
According to Danelfin AI, Castle Biosciences has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (53.78%) is +2.96% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Castle Biosciences stock?
Is it a good time to buy, sell, or hold Castle Biosciences stock right now?
Is Castle Biosciences undervalued right now?
What was the price range of Castle Biosciences stock over the past 12 months?
What is going on with Castle Biosciences stock in the last 3 months?
Does Castle Biosciences offer dividend payments?
What is the current market capitalization of Castle Biosciences?

Castle Biosciences Inc Company Profile

Castle Biosciences, Inc., an expert in molecular diagnostics, delivers sophisticated testing solutions designed to diagnose and treat a range of conditions, including dermatologic cancers, Barrett’s esophagus, uveal melanoma and various mental health disorders. Among the company's unique offerings is DecisionDx-Melanoma. This innovative gene expression profile (GEP) test ascertains the metastasis risk for patients afflicted with invasive cutaneous melanoma.

Beyond this is their proprietary DecisionDx-SCC, a GEP test engineered specifically for individuals diagnosed with cutaneous squamous cell carcinoma. For those faced with challenging melanocytic lesions diagnosis, Castle offers MyPath Melanoma. In cases of non-dysplastic Barrett’s esophagus or its indefinite dysplasia variant or low-grade dysplasia model? They rely on TissueCypher, a spatial omics tool designed to predict the potential development of high-grade dysplasia or even esophageal cancer.

Continuing their focus on predictive solutions is DecisionDx-UM, a unique GEP that predicts metastasis risk for patients burdened by uveal melanoma. On the psychiatry front, IDgenetix is introduced as an advanced pharmacogenomic evaluation tool that aids in optimizing medication prescriptions for major depressive disorder alongside schizophrenia, bipolar disorder anxiety disorders including social phobia and obsessive-compulsive personality disorder while also supportive in treating PTSD and ADHD.

Their products are meticulously designed for utilization in skin cancer sector as well as gastroenterology sphere and the mental health domain. Incorporated in 2007, Castle Biosciences rightfully calls Friendswood Texas home – it's headquarters location since inception.

Sector:
Country:United States
Industry:
Address:1500 W. Parkwood Ave., Suite 401, Friendswood
Employees:942
Website:castlebiosciences.com

Pros

High switching costs for physician test adoption

Proprietary diagnostic test intellectual property

Growing demand for precision oncology diagnostics

Recurring revenue from established test utilization

Operating leverage from scalable laboratory infrastructure

Cons

Reimbursement risk from payer policy changes

Evolving regulatory landscape for diagnostic tests

Competition from alternative diagnostic technologies

Challenges in physician integration into clinical pathways

Limited addressable market within specific cancer types

Company	AI Score	Compare
BMRABiomerica Inc
NEONeogenomics Inc
BDSXBiodesix Inc
WGSGeneDx Holdings Corp
LUCDLucid Diagnostics Inc

Company	AI Score	Compare
BMRABiomerica Inc
NEONeogenomics Inc
BDSXBiodesix Inc
WGSGeneDx Holdings Corp
LUCDLucid Diagnostics Inc

CSTL Stock AI Analysis